Manuel Benavides
Overview
Explore the profile of Manuel Benavides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
2233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moncayo C, Benitez C, Quintero V, Gonzalez C, Munoz J, Hernandez C, et al.
Jamba
. 2023 Dec;
15(1):1510.
PMID: 38059163
Contribution: This article presents the practical application of a participatory methodology to obtain information about the rural context and the knowledge and experience in the prevention and attention of environmental...
2.
Mulet N, Valladares-Ayerbes M, Vieitez J, Gravalos C, Garcia-Alfonso P, Santos C, et al.
Eur J Cancer
. 2022 Nov;
177:154-163.
PMID: 36335783
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients And Methods: Patients with mCRC and...
3.
Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C, et al.
Lancet Oncol
. 2022 Apr;
23(5):659-670.
PMID: 35427471
Background: Pembrolizumab has shown improved progression-free survival versus chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. However, the treatment's effect on overall survival in...
4.
Cuadros M, Cano C, Garcia-Rodriguez S, Martin J, Poyatos-Andujar A, Ruiz-Cabello F, et al.
BMC Med Genomics
. 2022 Mar;
15(1):45.
PMID: 35246124
Background: DNA methylation (DNAm) age metrics have been widely accepted as an epigenetic biomarker for biological aging and disease. The purpose of this study is to assess whether or not...
5.
Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez C, Vieitez J, Rivera F, et al.
Eur J Surg Oncol
. 2021 Dec;
48(5):1123-1132.
PMID: 34872775
Introduction: Retrospective studies and meta-analyses suggest that upfront primary tumour resection (UPTR) confers a survival benefit in patients with asymptomatic unresectable metastatic colorectal cancer (mCRC) undergoing chemotherapy, however a consensus...
6.
Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Munoz E, Rodriguez-Serrano E, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33916610
First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has shown some benefit. To accurately identify such patients before treatment, we studied blood biomarkers and primary tumor molecules....
7.
Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C, et al.
N Engl J Med
. 2020 Dec;
383(23):2207-2218.
PMID: 33264544
Background: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line...
8.
Sepulveda-Sanchez J, Gil-Gil M, Alonso-Garcia M, Salgado M, Vicente E, Mesia Barroso C, et al.
Target Oncol
. 2020 Oct;
15(5):613-622.
PMID: 33025213
Background: The cell cycle checkpoint G1/S, dependent on cyclin-dependent kinase (CDK) 4 amplification/overexpression and retinoblastoma phosphorylation, is altered in most anaplastic oligodendrogliomas (AOs). Objective: We aimed to evaluate the efficacy...
9.
Carrato A, Vieitez J, Benavides M, Rodriguez-Garrote M, Castillo A, Ogalla G, et al.
Eur J Cancer
. 2020 Sep;
139:51-58.
PMID: 32977220
Background: Although occasioned through different mechanisms, the potential neurotoxicity and also haematological toxicity of nab-paclitaxel and oxaliplatin-based chemotherapy regimen were studied in this trial, which aimed to determine the maximum-tolerated...
10.
Fernandez-Montes A, Gravalos C, Pericay C, Safont M, Benavides M, Elez E, et al.
Clin Colorectal Cancer
. 2020 Jun;
19(3):165-177.
PMID: 32507561
Colorectal cancer (CRC) is a public health problem: it is the third most common cancer in men (746,000 new cases/year) and the second in women (614,000 new cases/year), representing the...